Cardiometabolic multimorbidity was significantly associated with increased cerebrospinal fluid levels of phosphorylated tau (β = 0.165) and total tau (β = 0.065) compared to CMD-free individuals.
Cross-Sectional (n=1,464)
No
Does cardiometabolic multimorbidity increase cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults?
Cardiometabolic multimorbidity is associated with increased tau phosphorylation and neuronal injury biomarkers in cognitively normal adults, suggesting a potential mechanism linking cardiometabolic disease to Alzheimer's pathology.
Estimación del efecto: β = 0.165
valor p: p=0.037
BACKGROUND: Cardiometabolic multimorbidity is associated with an increased risk of dementia, but the pathogenic mechanisms linking them remain largely undefined. We aimed to assess the associations of cardiometabolic multimorbidity with cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) pathology to enhance our understanding of the underlying mechanisms linking cardiometabolic multimorbidity and AD. METHODS: This study included 1464 cognitively intact participants from the Chinese Alzheimer's Biomarker and LifestylE (CABLE) database. Cardiometabolic diseases (CMD) are a group of interrelated disorders such as hypertension, diabetes, heart diseases (HD), and stroke. Based on the CMD status, participants were categorized as CMD-free, single CMD, or CMD multimorbidity. CMD multimorbidity is defined as the coexistence of two or more CMDs. The associations of cardiometabolic multimorbidity and CSF biomarkers were examined using multivariable linear regression models with demographic characteristics, the APOE ε4 allele, and lifestyle factors as covariates. Subgroup analyses stratified by age, sex, and APOE ε4 status were also performed. RESULTS: A total of 1464 individuals (mean age, 61.80 years; age range, 40-89 years) were included. The markers of phosphorylated tau-related processes (CSF P-tau181: β = 0.165, P = 0.037) and neuronal injury (CSF T-tau: β = 0.065, P = 0.033) were significantly increased in subjects with CMD multimorbidity (versus CMD-free), but not in those with single CMD. The association between CMD multimorbidity with CSF T-tau levels remained significant after controlling for Aβ42 levels. Additionally, significantly elevated tau-related biomarkers were observed in patients with specific CMD combinations (i.e., hypertension and diabetes, hypertension and HD), especially in long disease courses. CONCLUSIONS: The presence of cardiometabolic multimorbidity was associated with tau phosphorylation and neuronal injury in cognitively normal populations. CMD multimorbidity might be a potential independent target to alleviate tau-related pathologies that can cause cognitive impairment.
Li et al. (Tue,) conducted a cross-sectional in Cognitively intact adults (n=1,464). Cardiometabolic multimorbidity vs. CMD-free was evaluated on Cerebrospinal fluid P-tau181 levels (β = 0.165, p=0.037). Cardiometabolic multimorbidity was significantly associated with increased cerebrospinal fluid levels of phosphorylated tau (β = 0.165) and total tau (β = 0.065) compared to CMD-free individuals.